Fractional CMO for HealthTech: Is It the Right Model for Your Stage?

A fractional CMO for HealthTech is a senior marketing leader who takes ownership of the marketing number for a share of the week, usually two or three days, for a year or more. She sits on the leadership team, sets the strategy, hires or directs the people who execute it, and reports pipeline to the board. The model exists because the judgement a company needs at Series A is a full-time CMO’s judgement, while the work it can fund and use is two days of it.

The role she steps into is senior and unstable everywhere. Spencer Stuart’s 2025 CMO tenure study, as reported by Marketing Dive, puts the average Fortune 500 CMO tenure at 4.3 years, below the C-suite average of 4.9, with 65% of departing CMOs moving up or across rather than out. Gartner’s 2025 CMO Spend Survey of 402 marketing leaders found budgets flat at 7.7% of revenue, 59% of CMOs saying the budget cannot deliver the strategy, and 39% planning to cut agency spend. A company that hires a full-time CMO too early buys a large salary for a plan it cannot fund, which is the gap a fractional CMO for HealthTech fills.

This guide sets out five tests for the founder or CEO of a HealthTech, digital health, MedTech or health SaaS company between seed and Series B, in the US, the UK or Europe. A note on candour: Healthora is a specialist agency, and this article is written to be fair to the fractional model, including the stages where a fractional CMO for HealthTech is the better choice. Our guide to the HealthTech marketing consultant covers the project-based alternative, and our pillar on the HealthTech marketing agency model covers ours.

1. The gap is judgement rather than hands

The first test for a fractional CMO for HealthTech is the shape of the gap. A company that has a plan and lacks the people to run it needs hands: an agency, a contractor, a hire. A company that has people producing pages, posts and campaigns and cannot say why the pipeline has not moved needs judgement. The fractional model supplies judgement with a small amount of hands. Buy it for the wrong gap and the company pays a senior day rate for work a junior could do.

A quick test to run this week

Ask three questions of whoever runs marketing today. Who is the buyer, by role and by the moment she starts searching? What is a qualified opportunity, in writing, agreed with sales? Which three activities produced the last ten opportunities? If the answers come back quickly and match what sales says, the gap is hands. If they come back as a list of channels and a shrug, the gap is judgement, and a fractional CMO for HealthTech is a candidate.

What judgement looks like in health

In health, the judgement includes things a generalist marketer has to learn on the job. The FDA’s or the MHRA’s classification of the product decides what the website may claim. HIPAA and GDPR shape the tracking the funnel depends on. A clinician reads evidence before benefits, and a procurement committee buys on an eighteen-month cycle. A fractional CMO for HealthTech arrives with that knowledge. One from fintech spends her first quarter acquiring it, on your budget.

2. You are inside the window

The second test is stage. The window for a fractional CMO for HealthTech opens when the company has its first paying customers and founder-led selling has stalled, and it closes when the company can fund and fully use a senior marketing leader five days a week. Before the window, there is no pipeline to own and the money is better spent on a diagnosis. After it, a fractional leader becomes a bottleneck, because decisions wait for Tuesday.

Where the window usually sits

For most health companies the window for a fractional CMO for HealthTech sits between a seed round with revenue and the year after Series A. Rock Health’s half-year report recorded $6.4 billion of US digital health funding across 245 deals in the first half of 2025, with the average deal at $26.1 million. A round of that size comes with a pipeline expectation and a hiring plan, and the marketing leader is rarely the first senior hire. The fractional model fills the eighteen months in between. Our guide to HealthTech growth strategy covers what the plan for those months contains.

Signs the window has closed

The window has closed when the marketing team has four or more people, when the CEO finds herself waiting for the fractional leader’s day to make decisions, or when the company is preparing a launch that needs someone in the building every day. At that point the fractional CMO for HealthTech should be helping to hire her replacement. At Healthora, we have seen that the companies which handle this transition well planned it from the first month, and the ones that handle it badly discovered the window had closed a year after it did.

3. Someone can execute what she decides

The third test is whether decisions can become work. A fractional CMO for HealthTech on two days a week can set the positioning, choose the channels, write the plan and review the results. She cannot also write the pages, build the email sequences, run the paid media and update the site. If nobody else can, the engagement produces a plan and a list of things that did not happen. The company needs hands before it needs a fractional leader, or at the same time.

The three ways to supply the hands

A marketing generalist in-house, directed by the fractional CMO for HealthTech, is the cheapest and slowest, because one person learns every discipline at once. An agency is the fastest, because the disciplines are already staffed, and the fractional leader’s job becomes briefing and judging the work. Contractors sit in between, and most engagements use a mix. Gartner’s survey found 39% of CMOs planning to cut agency spend and 22% saying generative AI has reduced their reliance on agencies for creativity and strategy. Read that as a signal that the execution layer is being repriced, and the judgement layer is not.

How the fractional CMO and the agency divide the work

One division works. The fractional CMO for HealthTech owns the number, the positioning, the plan and the brief. The agency owns the production, the channels and the reporting against the brief. Between them sits the written brief, dated and signed. At Healthora, we have seen that engagements with a written brief and a monthly review between the fractional leader and the agency lead tend to produce qualified pipeline within two quarters. Engagements without one tend to produce two parties describing the same quarter differently.

4. The CEO will give the time

The fourth test is the one founders fail most often. A fractional CMO for HealthTech needs the CEO for two to three hours a week in the first quarter and about one thereafter. The hours go on settling the positioning, opening the sales pipeline data, introducing customers for interviews and making the decisions only a founder can make. A CEO who hires a fractional leader to stop thinking about marketing has bought the wrong thing. The leader can carry the thinking. She cannot carry the decisions.

What the time is spent on

Month one is diagnosis and access: the CRM, the analytics, the lost-deal notes, six customer conversations. Then month two is decisions: the buyer, the position, the claims the product’s regulatory status allows, the channels. Month three onward is a weekly review of one page of numbers and a monthly review with the board. The hours are few and they are fixed. A fractional CMO for HealthTech who cannot get them is working blind, and the pipeline report at quarter two will show it.

The access that matters most in health

Two things a health company must open to its fractional CMO for HealthTech on day one: the regulatory position of the product, because it bounds every claim on the website, and the sales team’s real objections, because a hospital’s procurement questions are the content plan. McKinsey’s 2024 B2B Pulse, drawn from nearly 4,000 decision makers, found buyers using an average of ten channels in a purchase and splitting roughly a third each between in-person, remote and self-serve. The fractional leader decides which of those ten the company will be present in, and she cannot decide it without the sales data.

5. There is an end state

The fifth test is whether the engagement has somewhere to go. A fractional CMO for HealthTech is a bridge, and a bridge has two ends. At the far end sits either a full-time marketing leader the fractional CMO helped to hire, or a stable programme a smaller team can run with an agency and a quarterly strategy review. An engagement with no end state drifts into a permanent part-time executive, which is the most expensive way to run a marketing team of one.

Write the end state in month one

The end state is a sentence. “By month twelve, the company has a head of marketing in post and a documented positioning. The channel plan produces qualified pipeline at an agreed cost per opportunity, and the board trusts the reporting.” The fractional CMO for HealthTech then works backwards from it. She writes the job description for her successor in month nine, sits on the interview panel in month ten and hands over in month twelve. Our guide to outgrowing a HealthTech marketing agency covers the same transition from the agency side.

When the end state is a programme, and no hire

Some health companies never need a full-time CMO, and a fractional CMO for HealthTech is the last senior marketer they hire. A MedTech company selling one device to one specialty, or a health SaaS business with a narrow buyer, can run for years on a documented programme, an agency and a quarterly strategy review. The fractional leader’s end state there is the programme: written down, measured, and runnable by a marketing manager. Either end state is fine. The failure is having neither.

A fractional CMO for HealthTech in practice: the first ninety days

A fractional CMO for HealthTech engagement that passes the five tests runs its first quarter in three moves. Weeks one to four are diagnosis and access. The data is pulled from search, analytics and the CRM. Six customers and two lost deals are interviewed. The site and every claim are read against the product’s regulatory position, and the three problems that explain most of the pipeline gap are named. Then weeks five to nine are decisions: the buyer named by role and moment, the positioning written and tested, the channels chosen, the brief to the agency or the team signed. Weeks ten to thirteen are the first cycle.

In that first cycle the rebuilt pages go live, the first campaigns run, and the one-page pipeline report reaches the board.

Companies that run the quarter this way usually notice the change first in the sales conversation. Buyers arrive from the right searches having read the new positioning, and the first call starts from the problem rather than the product. Demo requests from the rebuilt pages follow, and by the second quarter the report shows qualified pipeline and cost per opportunity on a framework the board did not have before. A fractional CMO for HealthTech is judged on that report and on the state of the team at month twelve.

The recap below lists the five tests in the order to run them.

A fractional CMO for HealthTech is one way to put senior judgement into a health company before it can afford five days of it. The other ways are a consultant for a defined project, an agency with a strategy layer, or an early full-time hire. Our pillar guide to the HealthTech marketing agency model sets out how the options compare, and our services and case studies show what the agency side looks like in practice.

A specialist in health understands that the buyer forms her view long before the first call, that the claims on the website are bounded by a regulator, and that pipeline is the only number a board will accept. Run the five tests. If the answer is a fractional CMO for HealthTech, write the end state before the first invoice. If the answer is something else, the tests will have told you what.

Frequently asked questions

Keep reading

More on choosing and running marketing leadership in health: